2.Inhibition of pathological angiogenesis of Chinese medicine against liver fibrosis.
Chinese journal of integrative medicine 2016;22(8):569-572
Pathological angiogenesis of liver which includes liver sinusoidal capillarization due to lose of fenestraes of liver sinusoidal endothelial cells (LSECs) and formation of new vascular, is a crucial mechanism responsible for origination and development of liver fifibrosis and closely involves in the development of cirrhosis and hepatic cancer. Anti-neovascularization medicine such as sorafenib can decrease portosystemic shunts, improve splanchnic hyperdynamic circulation, lower portal hypertension, while it can not be applied in clinic due to its serious toxic and side reactions. Chinese herbal formula can effectively inhibit pathological angiogenesis of liver, improve microcirculation of liver, and decrease the probability of gastrointestinal hemorrhage in cirrhotic patients. Different Chinese herbal formula are of different characteristics on inhibiting pathological angiogenesis in liver fifibrosis, which partly explains synergistic effect of different compatibility of Chinese materia medica and opens up good vista for Chinese medicine against liver fifibrosis through inhibiting angiogenesis.
Drugs, Chinese Herbal
;
pharmacology
;
therapeutic use
;
Esophageal and Gastric Varices
;
complications
;
drug therapy
;
Hemorrhage
;
complications
;
drug therapy
;
Humans
;
Liver Cirrhosis
;
complications
;
drug therapy
;
Microcirculation
;
drug effects
;
Neovascularization, Pathologic
;
complications
;
drug therapy
3.Clinical effect and safety of somatostatin in treatment of postoperative gastrointestinal bleeding in neonates.
Bo-Xiang QI ; Lei ZHU ; Lei SHANG ; Li-Ping SHENG ; Bao-Li HU ; Kun GAO
Chinese Journal of Contemporary Pediatrics 2016;18(11):1065-1068
OBJECTIVETo investigate the clinical effect and safety of somatostatin in the treatment of postoperative gastrointestinal bleeding in neonates.
METHODSA prospective randomized study was performed, and 126 neonates who underwent surgery for congenital gastrointestinal anomalies were randomly divided into control group, treatment group A, and treatment group B. The neonates in the control group were given routine postoperative hemostasis, and those in the treatment groups were given somatostatin in addition to the treatment for the control group. The neonates in treatment group A were given intravenous injection of somatostatin 0.25 mg as the initial dose and 0.25 mg/h for maintenance, and those in treatment group B were given continuous intravenous pumping of somatostatin at a dose of 3.5 μg/(kg·h). The clinical outcome and complications were compared between the three groups.
RESULTSCompared with the control group, the treatment groups had significantly shortened clearance time in occult blood test for gastrointestinal decompression drainage and a significantly lower degree of the reduction in 24-hour hemoglobin (P<0.05), while there were no significant differences between treatment groups A and B. Compared with the control group, treatment group A had significant reductions in heart rate (HR), respiratory rate (RR), blood pressure (BP), and SaO2 after one hour of treatment (P<0.05 ), but there were no significant differences at the other time points between the two groups (P>0.05). There were no significant differences in monitoring indices between the control group and treatment group B (P>0.05). No neonates in the control group experienced hypoglycemia reaction, and treatment group A had a significantly higher incidence rate of hypoglycemia (20%) than treatment group B (P<0.05).
CONCLUSIONSSomatostatin has a marked clinical effect and good safety in the treatment of neonates with postoperative gastrointestinal bleeding, and the administration of somatostatin by continuous intravenous pumping leads to fewer side effects.
Female ; Gastrointestinal Hemorrhage ; drug therapy ; Humans ; Infant, Newborn ; Male ; Postoperative Complications ; drug therapy ; Prospective Studies ; Somatostatin ; adverse effects ; therapeutic use
4.A rare cause of spontaneous bleeding per oral in an elderly.
Fairuz Mohd IBRAHIM ; Irfan MOHAMAD
Annals of the Academy of Medicine, Singapore 2010;39(10):817-818
Aged
;
Female
;
Humans
;
Lingual Thyroid
;
complications
;
drug therapy
;
physiopathology
;
Oral Hemorrhage
;
diagnosis
;
etiology
;
physiopathology
6.A case of Wegener's granulomatosis complicated by diffuse pulmonary hemorrhage and thrombotic thrombocytopenic purpura.
Hong Euy LIM ; Sang Kyung JO ; Sang Wook KIM ; Hyun Kyung CHOI ; In Beom SUH ; Soo Young YOON ; Jeong Seok MOON ; Nam Hee WON ; Young Joo KWON ; Heui Jung PYO
The Korean Journal of Internal Medicine 1998;13(1):68-71
Wegener's granulomatosis is a distinct form of necrotizing granulomatous vasculitis which usually affects the kidneys and the upper and lower respiratory tracts. Unusual manifestations have also been reported, and these include colitis, urethritis and diabetes insipidus. We describe a case of Wegener's granulomatosis which presented with rapidly progressive renal insufficiency, sudden deafness, red eye, facial palsy, and complicated by uncommon manifestations that were diffuse pulmonary hemorrhage and thrombotic thrombocytopenic purpura.
Aged
;
Cyclosporine/therapeutic use
;
Female
;
Hemorrhage/complications*
;
Human
;
Lung Diseases/complications*
;
Prednisolone/therapeutic use
;
Purpura, Thrombotic Thrombocytopenic/complications*
;
Wegener's Granulomatosis/drug therapy
;
Wegener's Granulomatosis/diagnosis
;
Wegener's Granulomatosis/complications*
7.Clinical characteristics and prognosis of seizures in 75 children with acute lymphoblastic leukemia.
Jing LIU ; Ai Dong LU ; Ying Xi ZUO ; Jun WU ; Zhi Zhuo HUANG ; Yue Ping JIA ; Ming Ming DING ; Le Ping ZHANG ; Jiong QIN
Journal of Peking University(Health Sciences) 2022;54(5):948-953
OBJECTIVE:
To investigate the clinical characteristics, treatment, and prognosis of seizures in children with acute lymphoblastic leukemia (ALL) during chemotherapy.
METHODS:
Children with ALL with seizures during chemotherapy admitted to the Department of Pediatrics, Peking University People's Hospital from January 2010 to March 2022 were retrospectively analyzed. Clinical data including the incidence of seizure, time at seizure onset, causes, management, and prognosis were collected retrospectively.
RESULTS:
A total of 932 children with ALL were admitted during the study period, of whom, 75 (8%) were complicated with seizures during the period of chemotherapy. There were 40 males and 35 females, with a median age of 7.5 (1-17) years, and 43 cases (57.3%) occurred within the first 2 months of chemotherapy. The underlying diseases were reversible posterior encephalopathy syndrome (n=15), cerebral hemorrhage (n=10, one of whom was complicated with venous sinus thrombosis), intrathecal or systemic methotrexate administration (n=11), brain abscess (n=7, fungal infection in 3 cases, and bacterial in 4), viral encephalitis (n=2), febrile seizure (n=7), hyponatremia (n=7), hypocalcemia (n=2), and unknown cause (n=14). Sixty-four children underwent neuroimaging examination after seizure occurrence, of whom 37 (57.8%) were abnormal. The electroencephalograhpy (EEG) was performed in 44 cases and was abnormal in 24 (54.4%). Fifty-five patients remained in long-term remission with regular chemotherapy, 8 patients received hematopoietic stem cell transplantation, 9 died and 3 lost to follow-up. Symptomatic epilepsy was diagnosed in 18 cases (24%), and was well controlled in 16 with over 1 year of seizure-free. Whereas 2 cases were refractory to anti-seizure medications.
CONCLUSION
Seizures are relatively common in children with ALL, most commonly due to reversible posterior encephalopathy syndrome, methotrexate-related neurotoxicity, and cerebral hemorrhage. Seizures occurred within 2 months of chemotherapy in most cases. Neuroimaging and EEG should be performed as soon as possible after the first seizure onset to identify the etiology and to improve the treatment regimen. Some cases developed symptomatic epilepsy, with a satisfactory outcome of seizure remission mostly after concurrent antiseizure medication therapy.
Adolescent
;
Brain Diseases/complications*
;
Cerebral Hemorrhage/complications*
;
Child
;
Electroencephalography
;
Epilepsy/drug therapy*
;
Female
;
Humans
;
Male
;
Methotrexate/adverse effects*
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*
;
Prognosis
;
Retrospective Studies
8.Management of variceal hemorrhage: current status.
Chinese Medical Journal 2009;122(7):763-765
9.Intestinal Paragonimiasis with Colonic Ulcer and Hematochezia in An Elderly Taiwanese Woman.
Chung Te LIU ; Yen Cheng CHEN ; Tso Hsiao CHEN ; Ursula BARGHOUTH ; Chia Kwung FAN
The Korean Journal of Parasitology 2012;50(4):349-352
A 94-year-old female with end-stage renal disease presents with fever, fatigue, and hematochezia. She had previously resided in Hunan Province, China, and Myanmar, and she immigrated to Taiwan 30 years ago. Colonoscopy revealed a colonic ulcer. Biopsy of the colonic ulcer showed ulceration of the colonic mucosa, and many Paragonimus westermani-like eggs were noted. Serum IgG antibody levels showed strong reactivity with P. westermani excretory-secretory antigens by ELISA. Intestinal paragonimiasis was thus diagnosed according to the morphology of the eggs and serologic finding. After treatment with praziquantel, hematochezia resolved. The present case illustrates the extreme manifestations encountered in severe intestinal paragonimiasis.
Aged, 80 and over
;
Animals
;
Anthelmintics/therapeutic use
;
Antibodies, Helminth/blood
;
Antigens, Helminth/immunology
;
Colonic Diseases/complications/drug therapy/*pathology
;
Colonoscopy
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Gastrointestinal Hemorrhage/complications/drug therapy/*pathology
;
Humans
;
Intestinal Diseases, Parasitic/complications/drug therapy/parasitology/*pathology
;
Kidney Failure, Chronic/complications
;
Paragonimiasis/complications/drug therapy/parasitology/*pathology
;
Paragonimus westermani/*immunology
;
Praziquantel/therapeutic use
;
Taiwan
;
Ulcer/complications/drug therapy/*pathology
10.A case of hemophagocytic syndrome in a patient with fulminant ulcerative colitis superinfected by cytomegalovirus.
Jun Il MUN ; Sung Jae SHIN ; Byung Hyun YU ; Jee Hoon KOO ; Dong Hoon KIM ; Ki Myoung LEE ; Kwang Jae LEE
The Korean Journal of Internal Medicine 2013;28(3):352-355
Hemophagocytic syndrome (HPS) is an uncommon hematological disorder that manifests as fever, splenomegaly, and jaundice, with hemophagocytosis in the bone marrow and other tissues pathologically. Secondary HPS is associated with malignancy and infection, especially viral infection. The prevalence of cytomegalovirus (CMV) infection in ulcerative colitis (UC) patients is approximately 16%. Nevertheless, HPS in UC superinfected by CMV is very rare. A 52-year-old female visited the hospital complaining of abdominal pain and hematochezia for 6 days. She was diagnosed with UC 3 years earlier and had been treated with sulfasalazine, but had stopped her medication 4 months earlier. On admission, her spleen was enlarged. The peripheral blood count revealed pancytopenia and bone marrow aspiration smears showed hemophagocytosis. Viral studies revealed CMV infection. She was treated successfully with ganciclovir. We report this case with a review of the related literature.
Antiviral Agents/therapeutic use
;
Colitis, Ulcerative/*complications/drug therapy
;
Cytomegalovirus Infections/*complications/drug therapy
;
Female
;
Ganciclovir/therapeutic use
;
Gastrointestinal Agents/therapeutic use
;
Gastrointestinal Hemorrhage/etiology
;
Humans
;
Lymphohistiocytosis, Hemophagocytic/drug therapy/*virology
;
Middle Aged
;
Sulfasalazine/therapeutic use
;
Superinfection/*complications